Lineage Cell Therapeutics (LCTX) EBITDA Margin Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 828,504.00 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7,261.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -7.76 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -2,649.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 9,003.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 30,461.00 |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -67,892.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67,892.00 |
| Mar 31, 2026 | -16,180.00 |
| Dec 31, 2025 | 24,759.00 |
| Sep 30, 2025 | 7,230.00 |
| Jun 30, 2025 | -62,238.00 |
| Mar 31, 2025 | -31,096.00 |
| Dec 31, 2024 | -12,170.00 |
| Sep 30, 2024 | 19,984.00 |
| Jun 30, 2024 | 96,612.00 |
| Mar 31, 2024 | 134,178.00 |
| Dec 31, 2023 | 135,221.00 |
| Sep 30, 2023 | 63,964.00 |
| Jun 30, 2023 | 150,277.00 |
| Mar 31, 2023 | 116,871.00 |
| Dec 31, 2022 | 20,706.00 |
| Sep 30, 2022 | 131,021.00 |
| Jun 30, 2022 | 129,609.00 |
| Mar 31, 2022 | 125,298.00 |
| Dec 31, 2021 | 127,690.00 |
| Sep 30, 2021 | 75,323.00 |